| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,010,000 |
| Market
Cap: |
189.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $4.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 935 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
35,147 |
128,372 |
194,168 |
376,382 |
| Total Sell Value |
$151,895 |
$457,369 |
$591,564 |
$2,613,056 |
| Total People Sold |
2 |
6 |
7 |
9 |
| Total Sell Transactions |
2 |
14 |
19 |
36 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Murdock Terry L |
Chief Operating Officer |
• – – |
2022-07-05 |
4 |
S |
$5.17 |
$3,351 |
D/D |
(648) |
20,907 |
|
-42% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2022-07-05 |
4 |
S |
$5.17 |
$3,351 |
D/D |
(648) |
73,207 |
|
-42% |
|
| Deese Willie A |
|
– • – |
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
14,389 |
|
- |
|
| Secor Alicia |
|
– • – |
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Schwalm Cynthia |
|
– • – |
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
15,889 |
|
- |
|
| Nicholson Garry A |
|
– • – |
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
14,389 |
|
- |
|
| Muir Glenn P |
|
– • – |
2022-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
185,358 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2022-02-07 |
4 |
OE |
$0.39 |
$5,850 |
D/D |
15,000 |
116,000 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2022-02-01 |
4 |
OE |
$0.30 |
$3,000 |
D/D |
10,000 |
73,855 |
|
- |
|
| Moses Jennifer K. |
CFO |
• – – |
2022-02-01 |
4 |
OE |
$3.72 |
$9,579 |
D/D |
2,333 |
37,888 |
|
- |
|
| Avagliano Mark |
Chief Business Officer |
• – – |
2022-01-05 |
4 |
S |
$10.61 |
$15,334 |
D/D |
(1,445) |
21,555 |
|
57% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2022-01-05 |
4 |
S |
$10.61 |
$15,334 |
D/D |
(1,445) |
63,855 |
|
57% |
|
| Hanson James S. |
General Counsel |
• – – |
2022-01-05 |
4 |
S |
$10.61 |
$15,334 |
D/D |
(1,445) |
25,555 |
|
57% |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2022-01-05 |
4 |
S |
$10.61 |
$15,334 |
D/D |
(1,445) |
21,555 |
|
57% |
|
| Moses Jennifer K. |
CFO |
• – – |
2022-01-05 |
4 |
S |
$10.61 |
$15,334 |
D/D |
(1,445) |
35,555 |
|
57% |
|
| Bailey John E. (jack) Jr. |
President and CEO |
• • – |
2022-01-03 |
4 |
S |
$10.41 |
$355,262 |
D/D |
(34,125) |
233,208 |
|
57% |
|
| Bailey John E. (jack) Jr. |
President and CEO |
• • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
46,000 |
267,333 |
|
- |
|
| Avagliano Mark |
Chief Business Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
23,000 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
65,300 |
|
- |
|
| Hanson James S. |
General Counsel |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
27,000 |
|
- |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
23,000 |
|
- |
|
| Perry Andrew |
Chief Commercial Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,020 |
|
- |
|
| Moses Jennifer K. |
CFO |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
37,000 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-11-09 |
4 |
OE |
$0.39 |
$15,600 |
D/D |
40,000 |
101,000 |
|
- |
|
| Perry Andrew |
Chief Commercial Officer |
• – – |
2021-08-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20 |
|
-22% |
|
328 Records found
|
|
Page 4 of 14 |
|
|
0.69 (16.08%) 
